Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin versus ALLR3 induction for pediatric first-relapse high-risk B-cell precursor acute lymphoblastic leukemia
2023-509810-13-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, open-label trial of inotuzumab ozogamicin, mitoxantrone, vincristine, dexamethasone, pegaspargase and 1 more in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Pfizer. Primary endpoint: MRD-negative CR/CRp/CRi at end of induction. Planned start May 2023; status: authorised.
02
Drugs
inotuzumab ozogamicinmitoxantronevincristinedexamethasonepegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2023-509810-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509810-13-00.